Expectations for September, page-48

@sarge17 I think Starpharma might come through on at least one DEP phase 2 in house trial readouts prior to the end of the quarter (next Friday) but again if it is not combined with a DEP license deal it wont do the share price any good


It is laughable to here JF in that latest video you mention claim how undervalued the share price is and what an 'overreaction to the AstraZeneca decision' there has been when none of the Starpharma Management, Directors or the Chairman have bought shares at this supposed 'undervalued' level in the last 9 months ? Plenty of opportunities in 2023 (9 months) to buy these supposed 'undervalued' shares outside of any blackout periods, although many on here will claim that is the reason why they haven't ? No ASX listed company has blackout periods that last for 9 months - just sayin'


5 business days remain next week if JF & Co. are to deliver something within their guidance period for once .... GLTAH